TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.
Sara Jiayang LiLourdes M Perez-ChadaJoseph F MerolaPublished in: Journal of psoriasis and psoriatic arthritis (2018)
Tumor necrosis factor a (TNF-α)-targeted therapies have expanded the therapeutic options for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA) and have significantly improved patients' quality of life. Paradoxically, anti-TNF-α agents may induce psoriatic eruptions or worsen preexisting psoriatic skin disease. Currently, there is no standard approach for the management of TNF inhibitor-induced psoriasis. Here, we conduct a literature review on TNF inhibitor-induced psoriasis and introduce a novel treatment algorithm for maintaining otherwise effective anti-TNF therapy versus switching to a different class as appropriate in the management of patients with IBD, RA, psoriasis, or PsA.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- high glucose
- prostate cancer
- interstitial lung disease
- diabetic rats
- machine learning
- end stage renal disease
- patients with inflammatory bowel disease
- atopic dermatitis
- chronic kidney disease
- oxidative stress
- deep learning
- case report
- ejection fraction
- endothelial cells
- stem cells
- mesenchymal stem cells
- bone marrow
- peritoneal dialysis
- patient reported
- smoking cessation
- stress induced